bioRxivCancer BiologyPreprint
Multi-omic analysis of colorectal adenocarcinoma identifies a new subtype of myofibroblastic cancer-associated fibroblast expressing high level of B7-H3 and with poor prognosis value.
Maelle PicardiD, Arnaud GuilléiD, Pascal FinettiiD, Bernadette de RauglaudreiD, Nadiya BelfiliD, Lenaïg Maescam, David Jérémie BirnbaumiD, François BertucciiD, Émilie MamessieriD
- Citations
- 0
Abstract
The high mortality rate of colorectal cancer (CRC) combined with the lack of non-toxic and efficient personalized treatments makes it urgent to develop new targeted therapies for this disease. B7-H3 appears to be a good target as it is overexpressed in tumor tissue compared to normal tissue. However, B7-H3 is a molecule with ambivalent functions and is expressed by different cell types. This complexity contributed to the delay in identifying cell subtypes that express B7-H3 and their potential role in colorectal oncogenesis. In this study, we used in silico bulk, single-cell, and spatial transcriptomic data to investigate the clinical and biological characteristics of tumors with high B7-H3 expression, the precise nature of cells expressing high level of B7-H3, and their temporal appearance during colorectal oncogenesis. We found that tumors with high B7-H3 expression corresponded to tumors with a predominant stroma composed mainly of fibroblasts. Among them, two subtypes of ecm-myCAF fibroblasts and pro-fibrotic pericytes specifically expressed high levels of B7-H3, the former being an independent factor for poor prognosis in CRC. Finally, by examining precancerous lesions, we report that fibroblast subtypes with high levels of B7-H3 appear early during oncogenesis, especially at the inflamed stage. We also shed light on the fact that anti-B7-H3 immunotherapies might therefore preferentially target cells from the microenvironment rather than the tumor cells. This is particularly important to understand the mode of action of the anti-B7-H3 antibody-drug conjugate, which is currently being tested in clinical trials in several solid tumors. HighlightsO_LIHigh level of B7-H3 expression is associated with poor prognosis in colorectal cancer C_LIO_LIB7-H3 is recurrently found expressed by two subtypes of cancer-associated fibroblasts (CAF): pro-fibrotic pericytes and ecm-myCAF C_LIO_LIB7-H3high ecm-myCAF subtype is an independent poor prognosis for survival C_LIO_LIB7-H3high ecm-myCAF is detectable in pre-cancerous inflamed colonic tissues C_LI
- organism: human
- assay: bulk RNA-seq
- assay: scRNA-seq
- assay: spatial transcriptomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: protein structure prediction
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High-resolution integrative analysis allows characterization and spatial annotation of normal and cancer-associated colon fibroblasts
Emma W Viitala, Ella S. Salminen, … Saara Ollila·bioRxiv·Jul 29, 2025
- Comprehensive characterization of tumor microenvironment in colorectal cancer via histopathology-molecular analysis
- RBPMS as a novel marker for cancer-associated fibroblasts in distinguishing left and right colorectal cancer sidedness
Sahira Syamimi Ahmad Zawawi, Ahmad Aizat Abdul Aziz, … Marahaini Musa·bioRxiv·Aug 5, 2025
- Tumor-Antagonizing Fibroblasts Secrete Prolargin as Tumor Suppressor in Hepatocellular Carcinoma
B. Chiavarina, R. Ronca, … A. Turtoi·bioRxiv·Jan 4, 2021
- Consensus molecular subtyping of colorectal cancers is influenced by goblet cell content
Samuel A. Miller, Ahmed H. Ghobashi, Heather M. O’Hagan·Cancer GeneticsPeer-reviewed·Jan 26, 2021
- A fibroblast-rich transcriptomic axis reflects stromal remodeling within the CMS4 phenotype in colorectal cancer
Yuxi Zheng, Shuqiang Hao, Chonghe Jiang·bioRxiv·Sep 22, 2026